Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Robison

Showing results (261-270 of 284) with videos related to

Pageof 29
Sort By:
ACS Chemical Neuroscience|March 12, 2026
Efficient In Vivo Pharmacological Inhibition of ΔFOSB, an AP-1 Transcription Factor, in the BrainSean McNeme, Anil Kumar, Yun Young Yim, et al.
Neuro-Oncology|April 17, 2025
A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Efficient <i>in vivo</i> pharmacological inhibition of ΔFOSB, an AP1 transcription factor, in brainSean McNeme, Anil Kumar, Yun Young Yim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform NeurofibromasBrian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Nucleic Acids Research|August 30, 2022
Chemically targeting the redox switch in AP1 transcription factor ΔFOSBAshwani Kumar, Galina Aglyamova, Yun Young Yim, et al.
Neuro-Oncology|April 3, 2020
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium studyNicole J Ullrich, Sanjay P Prabhu, Alyssa T Reddy, et al.
Discovery Medicine|July 29, 2011
Exome sequencing and unrelated findings in the context of complex disease research: ethical and clinical implicationsGholson J Lyon, Tao Jiang, Richard Van Wijk, et al.
Biological Psychiatry|March 20, 2025
Astrocytes Control Cocaine-Induced Synaptic Plasticity and Reward Through the Matricellular Protein HevinRaphaële Mongrédien, Augusto Anesio, Gustavo J D Fernandes, et al.
Nature Neuroscience|May 18, 2010
DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responsesVincent Vialou, Alfred J Robison, Quincey C Laplant, et al.
Neuron|December 27, 2011
Role for mTOR signaling and neuronal activity in morphine-induced adaptations in ventral tegmental area dopamine neuronsMichelle S Mazei-Robison, Ja Wook Koo, Allyson K Friedman, et al.
Pageof 29

Showing results (261-270 of 284) with videos related to

Sort By:
Pageof 29
ACS Chemical Neuroscience|March 12, 2026
Efficient In Vivo Pharmacological Inhibition of ΔFOSB, an AP-1 Transcription Factor, in the BrainSean McNeme, Anil Kumar, Yun Young Yim, et al.
Neuro-Oncology|April 17, 2025
A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Efficient <i>in vivo</i> pharmacological inhibition of ΔFOSB, an AP1 transcription factor, in brainSean McNeme, Anil Kumar, Yun Young Yim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform NeurofibromasBrian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Nucleic Acids Research|August 30, 2022
Chemically targeting the redox switch in AP1 transcription factor ΔFOSBAshwani Kumar, Galina Aglyamova, Yun Young Yim, et al.
Neuro-Oncology|April 3, 2020
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium studyNicole J Ullrich, Sanjay P Prabhu, Alyssa T Reddy, et al.
Discovery Medicine|July 29, 2011
Exome sequencing and unrelated findings in the context of complex disease research: ethical and clinical implicationsGholson J Lyon, Tao Jiang, Richard Van Wijk, et al.
Biological Psychiatry|March 20, 2025
Astrocytes Control Cocaine-Induced Synaptic Plasticity and Reward Through the Matricellular Protein HevinRaphaële Mongrédien, Augusto Anesio, Gustavo J D Fernandes, et al.
Nature Neuroscience|May 18, 2010
DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responsesVincent Vialou, Alfred J Robison, Quincey C Laplant, et al.
Neuron|December 27, 2011
Role for mTOR signaling and neuronal activity in morphine-induced adaptations in ventral tegmental area dopamine neuronsMichelle S Mazei-Robison, Ja Wook Koo, Allyson K Friedman, et al.
Pageof 29